ArticleFrontiers in oncology2025
Novel volumetric modulated arc therapy approach for lattice radiation therapy for bulky liver tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lattice radiation therapy (LRT) is a type of spatially fractionated radiation therapy that has emerged as an effective treatment approach for bulky solid tumors. RapidArc Dynamic (RAD) is a novel beam delivery approach that may be advantageous for LRT. The purpose of this Methods: Twenty patients with bulky liver tumors treated with RT were retrospectively identified. VMAT-LRT and RAD-LRT plans were generated for all patients. Lattice spheres were placed in a standardized hexagonal pattern with alternating high-dose spheres (vertex tumor volume high [VTVH], analogous to the peak dose) and low-dose control spheres (vertex tumor volume low [VTVL], analogous to the valley dose). Gross tumor volumes (GTVs)<1,000 cm Results: For all 20 cases, RAD-LRT achieved superior plan quality than VMAT-LRT, indicated by similar prescription dose coverage (group mean, VTVH D80: 20.40 Gy for VMAT-LRT, 20.50 Gy for RAD-LRT) but significantly lower valley dose (group mean, VTVL mean dose: 3.40 Gy for VMAT-LRT, 2.20 Gy for RAD-LRT, p<0.0001). Compared to VMAT-LRT, RAD-LRT required fewer planning structures (mean ± SD, 9 ± 1 for VMAT-LRT, 4 ± 1 for RAD-LRT), less planning time (26 ± 8 min for VMAT-LRT, 18 ± 11 min for RAD-LRT), and fewer treatment beams (5 ± 1 arcs for VMAT-LRT, 1 arc with 4 ± 1 static ports for RAD-LRT). RAD-LRT also had significantly higher peak-to-valley dose ratios (group mean, VTVH/VTVL D90 ratio: 8.92 for VMAT-LRT, 18.20 for RAD-LRT, p<0.0001). Conclusion: RAD may offer a unique approach to Lattice RT. RAD-LRT generated high quality plans with notable treatment planning efficiency, allowing for creation of quality plans without extensive planning time and LRT expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.